Skip to main content
. 2022 Aug 16;14:925227. doi: 10.3389/fnagi.2022.925227

FIGURE 2.

FIGURE 2

Aging-associated molecular phenotypes of trimethylamine N-oxide (TMAO)-treated midbrain organoids. (A) Schematics of TMAO treatment in midbrain organoid. (B) Representative phase-contrast images (upper) and quantification of organoid size (lower). (C) Relative mRNA expression levels of XBP1 and GRP78. (D) Relative IF images (left) and quantification of phosphorylated cAMP response element-binding protein-positive cells in indicated groups (8WMs). Hoechst was used for counter nuclei staining. (E) The relative mRNA expression level of CDKN1A, CDKN2A, and TP53. (F) Representative IF images (upper) and quantification (lower) of the p53-expressing cells in the indicated organoid group. (G) Representative IF images (upper) and quantification (lower) of the Lamin A/C and Tri-Me-K9 in the indicated organoid group. Data are AVE ± SD [P < 0.05(*), P < 0.01(**)].